NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is reminding investors that a securities class action has been filed against Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) and that November 21, 2022 is the deadline for appointment of lead plaintiff.

If you bought or otherwise acquired Fulgent securities during the period March 22, 2019 and August 4, 2022, inclusive (the “Collection Period”) and would like to discuss this case and our investigation, please contact Attorney Jeffrey Campisi at (212) 687-1980 or by email [email protected].

If you are a member of the proposed class, you can move the court by November 21, 2022 at the latest to serve as lead plaintiff for the alleged class. If you have losses, we encourage you to contact us to learn more about the Lead Plaintiff Proceedings. You do not have to seek lead plaintiff to participate in a possible recovery.

On August 4, 2022, after the market close, Fulgent released its second quarter 2022 financial results on file with the U.S. Securities and Exchange Commission on Form 10-Q and announced, among other things, that the SEC is investigating certain cases Reports for 2018 to the first quarter of 2020. Specifically, the company disclosed the following in the relevant part:

“The Company has received a Civil Investigative Demand (CID) issued by the U.S. Department of Justice under the False Claims Act relating to its investigation into allegations of medically unnecessary laboratory testing, improper billing for laboratory testing, and compensation received or paid in violation of the Anti-Kickback Statute and Stark Act. This CID is requesting information and records relating to certain of the Company’s customers identified in the CID, who account for a small portion of the Company’s revenue. The Company is fully cooperating with the US Department of Justice to promptly…